Valuation Models for Biopharmaceutical Stocks

Are Biotech Valuations in the "Bubblet" Phase? In September of 2013 we wrote about the valuations of biotechnology companies from an M&A perspective after the acquisition of Onyx Pharmaceuticals (ONXX) by Amgen at a price of $10.4B. We will attempt to develop a model going forward that...

Pin It on Pinterest